Sisram Medical Ltd announced a postponement in the dispatch of its shareholder circular covering the renewal of its continuing connected transactions.

The circular, initially scheduled for release no later than 21 October 2026, will now be sent on or before 30 October 2026. Management cited the need for additional time to finalize information as the sole reason for the delay.

The forthcoming document will detail: • The New Sublicense Agreement and the New Promotional Services Agreements, together with their proposed annual caps. • Analyses from the Independent Board Committee and an Independent Financial Adviser. • The notice convening an extraordinary general meeting where shareholders will vote on the renewed arrangements.

The announcement was authorized by Chairman Lior Moshe Dayan on behalf of the board. As of the announcement date, Sisram’s board comprises two executive directors, three non-executive directors and four independent non-executive directors.

No other timetable changes or transaction terms were disclosed. The company reaffirmed its intention to circulate the full documentation within the revised deadline.